BLSM Stock Forecast: Blossomhill Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 15 Aug 2026 — in the weakest quartile.
BLSM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Blossomhill Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (54): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BLSM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BLSM, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLSM appears on the weeks it earns a place.
BLSM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Blossomhill Therapeutics, Inc. (BLSM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −7.7×
- Price / sales
- —
- Price / book
- −3.1×
- EV / EBITDA
- −2.8×
Cheaper than 92% of US stocks
Cheaper than 96% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- 46.0%
- Return on assets
- −37.2%
- Dividend yield
- —
Higher than 92% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BLSM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Blossomhill Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BLSM stock
How does Ticker Nerd's model rank BLSM?
As at 15 Aug 2026, Blossomhill Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (54 of 100).
What is the BLSM stock forecast for 2030?
No analyst covering Blossomhill Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLSM are extrapolating price history, which says nothing about the business.
What does Blossomhill Therapeutics, Inc. do?
BlossomHill Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for oncology and autoimmune disorders.
About Blossomhill Therapeutics, Inc.
BlossomHill Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for oncology and autoimmune disorders. The company’s work centers on precision drug design aimed at addressing unmet medical needs, with an emphasis on targeted therapies that can overcome resistance mechanisms seen in complex diseases. Its current portfolio includes clinical programs in cancer treatment, particularly around genetically defined tumors, alongside research efforts in immune-mediated conditions. BlossomHill Therapeutics operates as a drug discovery and development platform, combining chemistry, translational research, and early clinical testing to advance candidates from design through trial stages. Headquartered in San Diego, California and founded in 2020, BlossomHill Therapeutics plays a specialized role in the biopharmaceutical market by contributing differentiated therapies for areas where existing treatment options remain limited.
CEO Dr. Jingrong Jean Cui Ph.D. · 63 employees · United States · https://bhtherapeutics.com